Publications by authors named "Robert Deuson"

Claim this Profile
I
Indirect treatment comparison of cabazitaxel for patients with metastatic castrate-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen.
Jon P Fryzek, Heidi Reichert, Nicholas Summers, Lindsay Townes, Robert Deuson

PLoS One· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost effectiveness of romiplostim for the treatment of chronic immune thrombocytopenia in Ireland.
Dawn Lee, Patrick Thornton, Alexander Hirst, Lucie Kutikova, Robert Deuson

Appl Health Econ Health Policy· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative net cost impact of the utilization of romiplostim and intravenous immunoglobulin for the treatment of patients with immune thrombocytopenia in Québec, Canada.
Martine Pettigrew, Kirsten Garces, Robert Deuson, Jeannine Kassis, Vincent Laroche

J Med Econ· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The burden of immune thrombocytopenia in adults: evaluation of the thrombopoietin receptor agonist romiplostim.
Robert Deuson, Mark Danese, Susan D Mathias, Marieke Schoonen, Jon Fryzek

J Med Econ· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of bleeding-related episodes in patients with immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care.
Roberto Stasi, Magaral Murali, Marc Michel, Jean-François Viallard, Aristoteles Giagounidis, Robert Deuson

Int J Hematol· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care.
David J Kuter, Susan D Mathias, Mathias Rummel, Romeo Mandanas, Aristoteles A Giagounidis, Robert R Deuson

Am J Hematol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel approach to the evaluation of bleeding-related episodes in patients with chronic immune thrombocytopenia.
Ilene Weitz, Miguel A Sanz, David Henry, Martin Schipperus, Bertrand Godeau, Robert Deuson

Curr Med Res Opin· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP).
Robert J Klaassen, Susan D Mathias, George Buchanan, James Bussel, Robert Deuson

Pediatr Blood Cancer· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measurement of utility values in the UK for health states related to immune thrombocytopenic purpura.
Agota Szende, John Brazier, Caroline Schaefer, Robert Deuson, John J Isitt

Curr Med Res Opin· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short-term and long-term failure of laparoscopic splenectomy in adult immune thrombocytopenic purpura patients: a systematic review.
Joseph Mikhael, Kelly Northridge, Karla Lindquist, Craig Kessler, Robert Deuson

Am J Hematol· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost and mortality associated with hospitalizations in patients with immune thrombocytopenic purpura.
Mark D Danese, Karla Lindquist, Michelle Gleeson, Robert Deuson, Joseph Mikhael

Am J Hematol· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of corticosteroid-related symptoms in patients with immune thrombocytopenic purpura: results of a survey of 985 patients.
Dana Berti, Philip Moons, Fabienne Dobbels, Robert Deuson, Ann Janssens

Clin Ther· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The incidence and impact of thrombocytopenia in myelodysplastic syndromes.
Hagop Kantarjian, Francis Giles, Alan List, Roger Lyons, Mikkael A Sekeres, Robert Deuson

Cancer· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of chemotherapy-induced nausea and vomiting on health-related quality of life.
Enzo Ballatori, Fausto Roila, Benedetta Ruggeri, Maura Betti, Samanta Sarti, Robert R Deuson

Support Care Cancer· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cost of chemotherapy-induced nausea and vomiting in Italy.
Enzo Ballatori, Fausto Roila, Benedetta Ruggeri, Stella Porrozzi, Mauro Iannopollo, Robert Deuson

Support Care Cancer· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany.
Florian Lordick, Birgit Ehlken, Angela Ihbe-Heffinger, Karin Berger, Karl J Krobot, Robert Deuson

Eur J Cancer· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.
Brigitte Bloechl-Daum, Robert R Deuson, Panagiotis Mavros, Mogens Hansen, Jørn Herrstedt

J Clin Oncol· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians' and nurses' estimation vs. patients' reported outcomes.
Chi-Ting Liau, Nei-Min Chu, Hsueh-Erh Liu, Robert Deuson, Jade Lien

Support Care Cancer· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemotherapy-induced emesis: quality of life and economic impact in the context of current practice in Canada.
Jean Lachaine, Louise Yelle, Leonard Kaizer, Anick Dufour, Sean Hopkins, Robert Deuson

Support Cancer Ther· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemotherapy-induced nausea and vomiting in routine practice: a European perspective.
Agnes Glaus, Cornelia Knipping, Rudolf Morant, Christel Böhme, Burkhard Lebert, Robert Deuson

Support Care Cancer· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of chemotherapy-induced nausea and emesis after modern antiemetics.
Steven M Grunberg, Robert R Deuson, Panagiotis Mavros, Olga Geling, Mogens Hansen

Cancer· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of universal Haemophilus influenzae type b vaccination starting at 2 months of age in the United States: an economic analysis.
Fangjun Zhou, Kristine M Bisgard, Hussain R Yusuf, Robert R Deuson, Sue K Bath

Pediatrics· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis